Louis Garguilo

The House Rules Committee did not include the BIOSECURE Act in the National Defense Authorization Act (NDAA). I've been outspoken in defending @WuXi_AppTec’s right to due process. Readers have responded in spades. Here's the latest update. https://t.co/OWZ2hPVupY

“I’ve brought a little New Jersey litigator to Pittsburgh biotech,” says @BlueSphereBio CEO Kier Loiacono. And, as you'll read, to his #CDMO. His attorney-informed focus is applied to T cell receptor (TCR) technology. Here's part one of his insights. https://t.co/0cJSjsrci2

We love #AI. We hate #artificialintelligence. Now, we're getting hallucinations as well. What's a sentient being to do? Vincenzo Gioia and Remco Jan Geukes Foppen offer some assistance. https://t.co/PBLorY3SxG

Somewhere inside, is the thought: "I’d like to leave this job at my biopharma company." You wonder: "How would I start my own ... contract service organization?" Jeffrey Kiplinger Kiplinger, formerly of @pfizer, did just that. And wrote a book about it. https://t.co/nvBcgsvgXR

China-based CDMOs assist U.S.-based biotechnology organizations in developing and supplying drugs to U.S. patients. Western-based Big Pharma assists the development of China's industry and patients there. Which is under assault? https://t.co/dHxq0kxVLs

I took another look at H.R. 7085 (BIOSECURE Act). It’s a component of the #biopharma battle between the U.S. and #China, and altering your #drugdevelopment and #manufacturing #outsourcing options. My conclusions might be described as rather “ridiculous.”https://t.co/DHJIzGS3Yh

We are back online, and back at it: We need to continue to consider this situation regarding @WuXi_AppTec and #China https://t.co/GdSsMNOZ7w

To all connections here on X, the @OutsourcedPharm website/publication is down. Apologies for the inconvenience; our tech team is working on it. Despite that, wishes for a good start to the week for everyone.

I had no intention to write further about the Inflation Reduction Act (IRA) than I did in part one, but analyst/consultant Jesse Mendelsohn of Model N (a revenue optimization company) informs me there’s more we need to cover for our readers. https://t.co/0GX1WaN25T

BIO Expels WuXi, Agrees With U.S. Government. I don't necessarily agree ... https://t.co/2RjqLwljiZ

Difficult for me to understand. Here’s why. https://t.co/2RjqLwlR8x

Regarding an outsourcing Nirvana, says Mark Butchko, @EliLillyandCo, “I’d answer ‘bundle it all together. Then with a wry smile, “I want it all … Unfortunately, it doesn't always work as advertised.” #quality#pharmaceuticalindustry #supplychain https://t.co/Lm1drH4pVI

I have zero sympathies for the Chinese communist regime. My stance on tariffs and other economic and market-access blocking measures to combat the regime is more ambivalent. But is WuXi AppTec an enemy combatant against the citizens of the U.S.? https://t.co/ZoQ2OtIOX0

Direct from the acquirer's den. Perhaps just in time. https://t.co/sGj3FYTHz9

Novo Holdings acquiring @CatalentPharma, and @novonordisk taking in 3 fill-finish facilities, shakes up the #outsourcing industry at a time when so many #biopharma sponsors are already starved for capacity. https://t.co/KX3GYAAG6z

Why is Professor Thomas Rademacher’s U.K-based vaccine-creating biotech so important that Saudi Arabia has based the establishment of the Kingdom’s first vaccine manufacturing facility on the company? The narrative, interestingly, starts in Brazil. https://t.co/tAQYTS8Bky

Steve Fawell of @Amgen says we need to go beyond targeting proteins with well-defined pockets and find other ways to target the undruggable. He's got at least 2 ways in mind. https://t.co/nxleUXKodn